Overview Continuation Protocol to Protocol BBCO-001 Status: Completed Trial end date: 2017-12-01 Target enrollment: Participant gender: Summary This will be a multi-center, randomized withdrawal, open-label, non-treatment concurrent control, parallel group study. Patients completing protocol BBCO-001 will be offered the opportunity to enter into this 12-month randomized withdrawal protocol. Phase: Phase 3 Details Lead Sponsor: Bioblast Pharma Ltd.